health

US Approves Cheap Version Of HIV Prevention Shot

US Approves Cheap Version Of HIV Prevention Shot

The generic will be available for $40 per person per year in 120 countries, under a pricing agreement announced in September 2025 between Dr. Reddy’s and Unitaid, the African health research institute Wits RHI, and the Clinton Health Access Initiative (CHAI). “This is a moment of immense pride for all of us at Dr. Reddy’s,” said Deepak Sapra, CEO of Pharmaceutical Services and API at Dr. Reddy’s, in a statement.

The US Food and Drug Administration on Monday approved a low-cost version of a twice-yearly HIV prevention shot, bringing the breakthrough drug closer to market in low-income countries.

The approval was announced by Dr. Reddy’s Laboratories, the Indian maker of the generic version of lenacapavir, and by Unitaid, a global health initiative.

The generic will be available for $40 per person per year in 120 countries, under a pricing agreement announced in September 2025 between Dr. Reddy’s and Unitaid, the African health research institute Wits RHI, and the Clinton Health Access Initiative (CHAI).

“This is a moment of immense pride for all of us at Dr. Reddy’s,” said Deepak Sapra, CEO of Pharmaceutical Services and API at Dr. Reddy’s, in a statement.

“Developing and manufacturing a complex long-acting injectable like lenacapavir at an affordable price required strong scientific capabilities and manufacturing expertise to address an urgent access need.”

“Unitaid’s early risk-taking is helping shorten the time between a scientific breakthrough and real access in countries,” added Philippe Duneton, Unitaid’s executive director.

Lenacapavir was first developed by US pharmaceutical company Gilead and approved in June 2025 after proving more than 99.9 percent effective in large clinical trials.

A twice-yearly injectable that is akin to a vaccine — albeit without training the immune system — can be a more effective way to administer HIV preexposure prophylaxis (PrEP) than daily pills, which first won US approval in 2012 but only work if taken consistently.

But lenacapavir’s high cost — roughly $28,000 per year in the US, though insurance lowers what patients pay — was a major obstacle to its becoming a game-changer against a disease that has killed over 40 million people in four decades.

In late 2024, Gilead granted voluntary licenses for lenacapavir to six generic manufacturers, including Dr. Reddy’s.

“Even before generic availability, over 125,000 people in 10 early adopter African countries have already started Gilead’s lenacapavir,” Unitaid’s statement said.

The approval was granted under the US FDA’s President’s Emergency Plan for AIDS Relief (PEPFAR) program, Dr. Reddy’s said.

  • version
  • hiv
  • reddy
  • lenacapavir
  • unitaid
  • prevention
  • shot
  • country

Summaries and tags are generated automatically. Stay informed with VidiaNews.

Related news

‘Our Culture’: Deaf Nigerians Embrace Indigenous Sign Languages
lifestyle

‘Our Culture’: Deaf Nigerians Embrace Indigenous Sign Languages

Festus Zenda, Deaf Advocate and Indigenous Sign Language Promoter, with Nigeria’s National Agency for the Prohibition of Trafficking in Persons (NAPTIP), uses sign language to converse during a video call along a street in Abuja, on October 16, 2026. (Photo by LIGHT ORIYE TAMUNOTONYE / AFP) ‘Our culture and identity’ The government doesn’t completely ignore local sign languages: politicians often bring Hausa signers to campaign stops to court deaf voters, Zuba residents told AFP.

Read →
El Niño: Rising Climate Risks Deepen Economic Tensions
business

El Niño: Rising Climate Risks Deepen Economic Tensions

“In general, you can say it’s an extreme negative supply shock,” Paolo Zanghieri, an economist at Generali Asset Management, told AFP. “An El Niño characterised by a 2C rise in Pacific Ocean temperature could lift global food prices by up to 20 percent” by the first quarter of 2028, Zanghieri and his colleague Guillaume Tresca, an emerging markets strategist, wrote in a recent report.

Read →
Kenya targets paediatric HIV treatment gaps in World AIDS Day campaign
health

Kenya targets paediatric HIV treatment gaps in World AIDS Day campaign

NAIROBI, Kenya, Nov 21– Children, adolescents and young people account for 55 per cent of new HIV infections in Kenya, exposing a widening gap in the country’s fight against AIDS despite a significant decline in overall infections. The National Empowerment Network of People Living with HIV/AIDS in Kenya (NEPHAK) raised concerns last year that some members were being charged between Sh500 and Sh2,000 for HIV tests that had previo

Read →
Judge bans Trump’s restrictions on HIV funds for transgender patients
health

Judge bans Trump’s restrictions on HIV funds for transgender patients

The Trump administration cannot impose restrictions barring healthcare providers that receive certain federal HIV-treatment ⁠funds from acknowledging the gender identity ⁠of their transgender patients ​or from providing them with gender-affirming care, a federal judge ruled on Thursday. US district judge William Young in Boston sided with a group of national HIV medical associations and ⁠healthcare providers that challenged grant funding conditions imposed by the administration last year after Trump signed an executive order prohibiting federal funding for what he calls “gender ideology”.

Read →
11 Dead, Over 180 Hospitalised After Drinking Illicit Alcohol In India
health

11 Dead, Over 180 Hospitalised After Drinking Illicit Alcohol In India

At least 11 people have died, and more than 180 have been hospitalised after drinking suspected tainted alcohol in India’s northeastern state of Manipur. In May, at least 15 people died after drinking methanol-laced illicit liquor in Pune and neighbouring Pimpri-Chinchwad in the western state of Maharashtra.

Read →